The FDA clearance is a regulatory milestone but lacks near-term revenue path since the company explicitly will not commercialize without an AI-ECG algorithm. The value realization depends on either a future AI-ECG clearance or a sale/license of the device IP. Monitor for any AI-ECG algorithm submission or partnership/licensing announcements, and watch the Fortitude merger closing timeline.
Price Chart
Executive Summary
HeartSciences received FDA 510(k) clearance for its MyoVista wavECG device as a 12-lead resting electrocardiograph, but the company explicitly stated it does not intend to commercialize the device without a cleared AI-ECG algorithm and has no timeline for commercialization. The clearance broadens potential options for the device and related IP, but the company's commercial focus remains on MyoVista Insights, and the proposed merger with Fortitude Mining is expected to close in Q4 2026.
Key Facts
- FDA granted 510(k) clearance (K260005) for MyoVista wavECG device as a 12-lead resting electrocardiograph.
- Clearance covers acquisition and interpretation of ECG signals from adult and pediatric patients in hospitals and healthcare facilities.
- Clearance does NOT include an AI-ECG algorithm.
- Company does not intend to commercialize the device without a cleared AI-ECG algorithm and has made no commitment to, and has no timeline for, commercialization.
- Proposed business combination with Fortitude Mining Holdings, Inc. expected to close in Q4 2026, subject to shareholder approval and customary conditions.
Financial Impact
No financial figures disclosed; the clearance broadens IP asset value but commercialization is not planned without AI-ECG algorithm clearance.
Risk Factors
- Company has no timeline or commitment to commercialize the cleared device without an AI-ECG algorithm.
- Proposed merger with Fortitude is subject to shareholder approval and may not close as expected.
- No financial data or revenue guidance provided in this filing.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-107238 |
| Document: ea030780201ex99-1.htm | 0001213900-26-107238 |
| Document: 0001213900-26-107238-index-headers.html | 0001213900-26-107238 |
| Document: 0001213900-26-107238-index.html | 0001213900-26-107238 |
| Document: 0001213900-26-107238.txt | 0001213900-26-107238 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | DEFA14A | $3.18 | awaiting T+1 | — | $3.28 (+3.08%) |
Oct 26, 2026 1d ago | DEFA14A | $3.18 | awaiting T+1 | — | $3.28 (+3.14%) |
Oct 26, 2026 1d ago | DEFA14A | $3.18 $3.28 | ▲ +3.14% | ▲ +2.58% | $3.28 (+3.14%) |
Oct 23, 2026 3d ago | SC 13D/A | $3.18 $3.28 | ▲ +3.14% | ▲ +2.58% | $3.28 (+3.14%) |
Oct 21, 2026 6d ago | DEFA14A | $3.17 $3.14 | ▼ −0.95% | ▼ −0.42% | $3.28 (+3.47%) |
Oct 19, 2026 8d ago | DEFA14A | $3.13 $3.56 | ▲ +13.74% | ▲ +13.21% | $3.28 (+4.79%) |
Oct 19, 2026 8d ago | DEFA14A | $3.07 $3.13 | ▲ +1.95% | ▲ +1.62% | $3.28 (+6.84%) |
Oct 19, 2026 8d ago | DEFM14A | $3.07 $3.13 | ▼ −1.95% | ▼ −1.62% | $3.28 (−6.84%) |
Oct 15, 2026 12d ago | DEFA14A | $3.02 $3.07 | ▲ +1.66% | ▲ +1.23% | $3.28 (+8.61%) |
Oct 9, 2026 18d ago | 424B5 | $3.30 $3.09 | ▲ +6.36% | ▲ +6.35% | $3.28 (+0.61%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers